Gilead Sciences (GILD)

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

Gilead Sciences (NASDAQ:GILD) is preparing for a potential launch of its multiple myeloma cell therapy anito-cel, with plans to build on the treatment-center relationships and manufacturing capabilities established by its existing CAR-T products, a company executive said. Cindy Perettie, executive

The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.

Enrollment in the MAIA-Ovarian trial is complete and data is due by early 2027.

Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.

These are among the best the industry has to offer.

Gilead deal and 2028 cash runway frame upcoming hepatitis data.

Gilead Sciences increased its quarterly dividend by 3.8% this year.

Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company’s third-quarter earnings call. The company

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be announcing earnings results this Wednesday afternoon. Here’s what to expect. Myriad Genetics mi...

Biotech company Amgen (NASDAQ:AMGN) will be reporting results this Tuesday after market hours. Here’s what you need to know. Amgen beat analysts’ revenue exp...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. Bio...

The company is having a great year.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...

Base business sales surged 16%, marking strongest growth in over a decade.

Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove performance. The company also raised its full-year base business revenue outlook while outlining t